Patheon Appoints Michel Lagarde President
PTSM: Pharmaceutical Technology Sourcing and Management
Lagarde will be based out of the company’s Boston office and will lead Patheon’s global corporate and cross-enterprise operations.
On May 31, 2016, Patheon announced that it has appointed Michel Lagarde president of the company. Lagarde will be based out of the company’s Boston office and will lead global corporate and cross-enterprise operations. He will report to the Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy and oversee its business segments, sales and marketing, and quality functions.
Lagarde joins Patheon from JLL Partners, a middle market private equity firm. For the past eight years, he has been working with several of JLL’s portfolio companies, including Patheon, in the healthcare and pharma services sectors as managing director. He has served as a member of Patheon’s Board of Directors since 2011. As a result of his appointment, Lagarde has stepped down from his position on Patheon’s Board of Directors.
Source: Patheon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
